Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4 ...

Filoviruses are among the globe's most lethal—indeed, so dangerous they can be handled only in high-security laboratories.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Jenny Strasburg is a reporter in London, where she writes for The Wall Street Journal about oil and gas, climate, the ...

Novavax faces a setback as the FDA requests an additional trial for COVID-19 vaccine approval. Read more here.

Federal regulators are asking Novavax to complete an additional randomized clinical trial on its Covid-19 vaccine after ...

Major drug companies are beginning to deliver their first-quarter readouts to Wall Street analysts, revealing their ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

Sara Castellanos is a news editor on The Wall Street Journal's Live Journalism team in New York, where she plans on-stage ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...